SRI Biosciences provides complete drug and biologic discovery and development capabilities to take drugs from "Idea to IND." Learn how SRI can help you move your lead compound from the lab bench to the clinic by clicking on the map below, on the subject list to the right, or the detailed site map.
 

Featured Capability: Molecular Morphology Press Releases: Lidia Sambucetti Joins SRI International to Lead Cancer Drug Discovery Programs Read the Release SRI International Awarded National Institute of Allergy and Infectious Diseases Contract to Develop Drugs and Therapeutics For HIV and AIDS-Associated Infections Read the Release Steven Samuelsson Joins SRI International's Bioscience Division as Director of Imaging Read the Release SRI International Awarded National Cancer Institute Contract to Evaluate Potential Cancer Drugs Read the Release More SRI News Upcoming Conferences and Events More Information Publications View recent publications

SRI Biosciences is a unique organization of approximately 230 people, with all of the resources necessary to take chemical and biological research programs from "idea to IND"™ — from initial discoveries to investigational new drug applications to start human clinical trials. The Biosciences Division performs basic research on disease mechanisms like an academic institution; drug discovery and the development of biologics like a biotechnology or pharmaceutical company; and full-service preclinical contract research and development like a CRO (contract research organization).  

SRI has been providing industry leaders, emerging companies, and government agencies with a broad range of pharmaceutical discovery and development capabilities since the 1950s. Our clients and partners have long benefited from the multidisciplinary expertise of our technical staff, strict adherence to regulatory guidelines, and the convenience of having all our resources at one location.

Contact Us

     Last Updated Jun 18, 2008